化学
生物利用度
药理学
立体化学
铅化合物
药品
顺反异构体
结构-活动关系
生物化学
肽基脯氨酰异构酶
体外
异构酶
酶
医学
作者
Richard L. Mackman,Victoria A. Doughty,David K. Dean,Petr Jansa,Karine G. Poullennec,Todd C. Appleby,Carol Austin,Caroline A. Blakemore,Ruby Z. Cai,Carina E. Cannizzaro,Gregory M. Chin,Jean‐Yves Chiva,Neil A. Dunbar,Hans G. Fliri,Adrian J. Highton,Hon C. Hui,Mingzhe Ji,Haolun Jin,Kapil Karki,Andrew J. Keats
标识
DOI:10.1021/acs.jmedchem.8b00802
摘要
Cyclophilins are a family of peptidyl-prolyl isomerases that are implicated in a wide range of diseases including hepatitis C. Our aim was to discover through total synthesis an orally bioavailable, non-immunosuppressive cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus (HCV) activity that could serve as part of an all oral antiviral combination therapy. An initial lead 2 derived from the sanglifehrin A macrocycle was optimized using structure based design to produce a potent and orally bioavailable inhibitor 3 . The macrocycle ring size was reduced by one atom, and an internal hydrogen bond drove improved permeability and drug-like properties. 3 demonstrates potent Cyp inhibition ( K d = 5 nM), potent anti-HCV 2a activity (EC 50 = 98 nM), and high oral bioavailability in rat (100%) and dog (55%). The synthetic accessibility and properties of 3 support its potential as an anti-HCV agent and for interrogating the role of Cyp inhibition in a variety of diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI